Journal
ONCOTARGET
Volume 8, Issue 49, Pages 85068-85084Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.18844
Keywords
ACKR3; CXCR4; chemokine; B cell; lymphoma
Categories
Funding
- Krebsforschung Schweiz [KFS 2891-02-2012]
- Swiss National Science Foundation [310030_163336]
- Helmut Horten Foundation
- Gelu Foundations
- Swiss National Science Foundation (SNF) [310030_163336] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Diffuse large B cell lymphoma (DLBCL) is the most frequent lymphoma accounting for more than the 30% of the cases. Involvement of extranodal sites, such as bone marrow and central nervous system, is associated with poor prognosis. A contribution of the chemokine system in these processes is assumed as it is known as a critical regulator of the metastatic process in cancer. The atypical chemokine receptor 3 (ACKR3), which does not couple to G-proteins and does not mediate cell migration, acts as a scavenger for CXCL11 and CXCL12, interfering with the tumor homing CXCL12/CXCR4 axis. Here, functional expression of ACKR3 in DLBCL cells was necessary for colonization of the draining lymph node in an in vivo subcutaneous lymphoma model. Moreover, in a disseminated in vivo lymphoma model, ACKR3 expression was required for bone marrow and brain invasion and local tumor growth. The present data unveil ACKR3 as potential therapeutic target for the control of tumor dissemination in DLBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available